RT Journal Article
SR Electronic
T1 Multi-population genome-wide association study implicates both immune and non-immune factors in the etiology of pediatric steroid sensitive nephrotic syndrome
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.09.13.22279644
DO 10.1101/2022.09.13.22279644
A1 Barry, Alexandra
A1 McNulty, Michelle T.
A1 Jia, Xiaoyuan
A1 Gupta, Yask
A1 Debiec, Hanna
A1 Luo, Yang
A1 Nagano, China
A1 Horinouchi, Tomoko
A1 Jung, Seulgi
A1 Colucci, Manuela
A1 Ahram, Dina F.
A1 Mitrotti, Adele
A1 Sinha, Aditi
A1 Teeninga, Nynke
A1 Jin, Gina
A1 Shril, Shirlee
A1 Caridi, Gianluca
A1 Bodria, Monica
A1 Lim, Tze Y
A1 Westland, Rik
A1 Zanoni, Francesca
A1 Marasa, Maddalena
A1 Turudic, Daniel
A1 Giordano, Mario
A1 Gesualdo, Loreto
A1 Magistroni, Riccardo
A1 Pisani, Isabella
A1 Fiaccadori, Enrico
A1 Reiterova, Jana
A1 Maringhini, Silvio
A1 Morello, William
A1 Montini, Giovanni
A1 Weng, Patricia L.
A1 Scolari, Francesco
A1 Saraga, Marijan
A1 Tasic, Velibor
A1 Santoro, Domenica
A1 van Wijk, Joanna A.E.
A1 Milošević, Danko
A1 Kawai, Yosuke
A1 Kiryluk, Krzysztof
A1 Pollak, Martin R.
A1 Gharavi, Ali
A1 Lin, Fangmin
A1 Simœs e Silva, Ana Cristina
A1 Loos, Ruth J.F.
A1 Kenny, Eimear E.
A1 Schreuder, Michiel F.
A1 Zurowska, Aleksandra
A1 Dossier, Claire
A1 Ariceta, Gema
A1 Drozynska-Duklas, Magdalena
A1 Hogan, Julien
A1 Jankauskiene, Augustina
A1 Hildebrandt, Friedhelm
A1 Prikhodina, Larisa
A1 Song, Kyuyoung
A1 Bagga, Arvind
A1 Cheong, Hae Il
A1 Ghiggeri, Gian Marco
A1 Vachvanichsanong, Prayong
A1 Nozu, Kandai
A1 Vivarelli, Marina
A1 Raychaudhuri, Soumya
A1 Tokunaga, Katsushi
A1 Sanna-Cherchi, Simone
A1 Ronco, Pierre
A1 Iijima, Kazumoto
A1 Sampson, Matthew G.
YR 2022
UL http://medrxiv.org/content/early/2022/09/14/2022.09.13.22279644.abstract
AB Pediatric steroid-sensitive nephrotic syndrome (pSSNS) is the most common childhood glomerular disease. Previous genome-wide association studies (GWAS) identified a risk locus in the HLA Class II region and three additional signals. But the genetic architecture of pSSNS, and its genetically driven pathobiology, is largely unknown. We conducted a multi-population GWAS meta-analysis in 38,463 participants (2,440 cases) and population specific GWAS, discovering twelve significant associations (eight novel). Fine-mapping implicated specific amino acid haplotypes in HLA-DQA1 and HLA-DQB1 driving the HLA Class II risk signal. Non-HLA loci colocalized with eQTLs of monocytes and numerous T-cell subsets in independent datasets. Colocalization with kidney eQTLs was lacking, but overlap with kidney cell open chromatin suggests an uncharacterized disease mechanism in kidney cells. A polygenic risk score (PRS) associated with earlier disease onset in two independent cohorts. Altogether, these discoveries expand our knowledge of pSSNS genetic architecture across populations and provide cell-specific insights into its molecular drivers.Competing Interest StatementThe authors have declared no competing interest.Funding StatementMGS is supported by NIH grants R01DK119380, RC2DK122397, 2U54DK083912 and a gift from The Pura Vida Kidney Foundation This study was funded by European Research Council grant ERC-2012- ADG_20120314 (grant agreement 322947) and Agence Nationale pour la Recherche Genetransnephrose grant ANR-16-CE17-004-01. The Nephrotic Syndrome Study Network (NEPTUNE) is part of the Rare Diseases Clinical Research Network (RDCRN), which is funded by the National Institutes of Health (NIH) and led by the National Center for Advancing Translational Sciences (NCATS) through its Division of Rare Diseases Research Innovation (DRDRI). NEPTUNE is funded under grant number U54DK083912 as a collaboration between NCATS and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Additional funding and/or programmatic support is provided by the University of Michigan, NephCure Kidney International and the Halpin Foundation. RDCRN consortia are supported by the RDCRN Data Management and Coordinating Center (DMCC), funded by NCATS and the National Institute of Neurological Disorders and Stroke (NINDS) under U2CTR002818. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This research program was approved by the IRB of Boston Children's Hospital.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in this present study are available upon reasonable request to the authors and will be subsequently uploaded to a data-sharing portal.